Lung Cancer

Lung Cancer News & Features

Following a smoking smoking cessation program.

Does Patient Interest Show a Need for Cessation Programs in Lung Cancer Multidisciplinary Clinics?

Joyce Pagan

June 2, 2020

Researchers surveyed consecutive new patients at a multidisciplinary clinic to determine smokers’ willingness to participate in a cessation program.

Opdivo Plus Yervoy With Limited Chemotherapy Approved for First-Line Metastatic or Recurrent NSCLC

Diana Ernst, RPh

June 1, 2020

The Food and Drug Administration (FDA) has approved the combination of Opdivo (nivolumab; Bristol Myers Squibb) plus Yervoy (ipilimumab; Bristol Myers Squibb) and 2 cycles of platinum-doublet chemotherapy, for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

Alunbrig Approved as First-Line Treatment for ALK-Positive Metastatic NSCLC

Brian Park, PharmD

May 28, 2020

The FDA has approved Alunbrig® (brigatinib; Takeda) as a first-line treatment of adults with anaplastic lymphoma kinase(ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Tecentriq Gains Approval for Additional Lung Cancer Indication

Brian Park, PharmD

May 26, 2020

The approval was based on data from the phase 3 IMpower110 study that compared the efficacy and safety of atezolizumab monotherapy to platinum-based chemotherapy in PD-L1-selected, chemotherapy-naive patients with stage IV NSCLC without ALK or EGFR mutations.

Cancer Survivorship: A Review of Strategies for Optimizing Patient Outcomes

Bette Weinstein Kaplan

May 25, 2020

A reflection on survivorship issues and up-to-date reports on current trends in treatment management.

Lung Cancer

Does Patient Interest Show a Need for Cessation Programs in Lung Cancer Multidisciplinary Clinics?

Opdivo Plus Yervoy With Limited Chemotherapy Approved for First-Line Metastatic or Recurrent NSCLC

Alunbrig Approved as First-Line Treatment for ALK-Positive Metastatic NSCLC

Tecentriq Gains Approval for Additional Lung Cancer Indication

Cancer Survivorship: A Review of Strategies for Optimizing Patient Outcomes

Lung Cancer Clinical Trials

Clinical Trial: Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

Clinical Trial: Improving Management of Breathlessness in Patients With Lung Cancer

Clinical Trial: Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Clinical Trial: Lung Cancer Biomarkers and Screening (NYULCBC)

Clinical Trial: Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)

Want to read more?

Alunbrig Approved as First-Line Treatment for ALK-Positive Metastatic NSCLC